Monotherapy in children and infants

Neurology

Volumn 69, Issue 24 SUPPL. 3, 2007, Pages

  Wilfong, Angus A ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b Texas Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CYTOCHROME P450; ERYTHROMYCIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; BEHAVIOR; BEHAVIOR DISORDER; BENIGN CHILDHOOD EPILEPSY; CHILD BEHAVIOR; CHILD PSYCHIATRY; CLINICAL DECISION MAKING; COGNITION; DISEASE CLASSIFICATION; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG TREATMENT FAILURE; FOCAL EPILEPSY; GROUPS BY AGE; HUMAN; HYPERACTIVITY; INTELLIGENCE QUOTIENT; IRRITABILITY; KETOGENIC DIET; MAJOR DEPRESSION; MENTAL DISEASE; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; TONIC CLONIC SEIZURE;

EID: 37349018722     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000302373.47100.1a     Document Type: Article

References (27)

1. Hauser WA. Epidemiology of epilepsy in children. Neurosurg Clin North Am 1995;6:419-429.
2. Holmes GL. Overtreatment in children with epilepsy. Epilepsy Res 2002;52:35-42.
3. Guerrini R. Epilepsy in children. Lancet 2006;367:499-524.
4. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(suppl 1):S1-56.
5. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epilepsy syndromes. Epilepsia 1989;30:389-399.
6. Carney PW, Prowse MA, Scheffer IE. Epilepsy syndromes in children. Aust Fam Physician 2005;34:1009-1015.
7. Sankar R. Initial treatment of epilepsy with antiepileptic drugs: pediatric issues. Neurology 2004;63(suppl 4):S30-39.
8. Brodie MJ. Medical therapy of epilepsy: when to initiate treatment and when to combine? J Neurol 2005;252:125-130.
9. Pellock JM. Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 1999;104:1106-1116.
10. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-1260.
11. Trileptal [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp., 2006.
12. Topamax [package insert]. Titusville, NJ: Ortho-McNeil Neurologics Inc., 2005.
13. Depakote ER [package insert]. North Chicago, IL: Abbott Laboratories, 2006.
14. Depakote tablets [package insert]. North Chicago, IL: Abbott Laboratories; 2006.
15. Depacon [package insert]. North Chicago, IL: Abbott Laboratories, 2006.
16. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273.
17. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-1120.
18. National Institute for Clinical Excellence. The epilepsies: diagnosis and management of the epilepsies in adults in primary and secondary care. 2004a. Available at: http://www.nice.org.uk/page.aspx?o=CG020adult. Accessed November 16, 2006.
19. Aldenkamp AP. De Krom M, Reijs R. Newer epileptic drugs and cognitive issues. Epilepsia 2003;44:21-29.
20. Loring DW, Meador KJ. Cognitive side effects of antiepileptic drugs in children. Neurology 2004;62:872-877.
21. Glauser TA. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neurol 2004;19(suppl 1):S25-38.
22. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 1999;40:1471-1483.
23. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80:909-917.
24. Novak PH, Ekins-Daukes S, Simpson CR, Milne RM, Helms P, McLay JS. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. Br J Clin Pharmacol 2005;59:712-717.
25. Pauwels O. Factors contributing to carbamazepinemacrolide interactions. Pharmacol Res 2002;45:291-298.
26. Kuzniecky RI, Mortati K. Practical strategies for switching to newer antiepileptic drugs. Rev Neurol Dis 2005;2:186-198.
27. Freeman J, Veggiotti P, Lanzi G, Tagliabue A, Perucca E. The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res 2006;68:145-180.